Skip to main content

Molecular Partners AG

corporate_fare Company Profile

Molecular Partners AG

MOLN·NASDAQ·Life Sciences·CIK 0001745114

The company is a clinical-stage biotechnology company focused on designing and developing DARPin therapeutics. These therapeutics are a new class of custom-built protein drug candidates based on natural binding proteins. The company's programs are in various stages of preclinical and clinical development, with a primary focus on oncology. DARPin therapeutics have been clinically validated across several therapeutic areas and developed to the registrational stage. The company utilizes the properties of DARPins, including high affinity and specificity, small size, flexible architecture, and high stability, to design differentiated therapeutics for cancer patients. These include targeted radiopharmaceuticals and next-generation immune cell engagers. DARPin candidates have been tested in preclinical studies and clinical trials, involving over 2,500 patients, and have shown high activity and general tolerability. The company has designed product candidates with multiple mechanisms of action (MoAs), such as blocking growth factors, localizing activity, conditionally activating immune cells (e.g., logic-gated Switch-DARPins), delivering cytotoxic payloads and radionuclides (e.g., Radio-DARPins), neutralizing viruses, adjusting half-life, and initiating cell death. The company applies these features across its portfolio to achieve specific therapeutic responses. Its DARPin platforms, including Radio-DARPins and Switch-DARPins, are designed to yield novel product candidates with broad therapeutic applications.

Molecular Partners AG (NASDAQ:MOLN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for MOLN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 9/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for MOLN spans 6-K, 20-F.

Recent high-impact activity:

  • Molecular Partners Flags Going-Concern Doubt, Cuts Up to 44% of Staff Alongside Q3 Results
  • MP0712 Advances to Higher Dose; H1 2026 Cash Runway Extends into Late 2027
  • Phase 2 Trial of MP0317 in Bile Duct Cancer Doses First Patients
  • Molecular Partners Provides Broad Clinical Pipeline Update: MP0712 Data Expected Soon, MP0726 FIH in H2
  • Molecular Partners Doses First Patients in Phase 1/2a Trial for Lead Radio-DARPin MP0712

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
CHF 0 CHF
Net Income
-CHF 61.65M CHF
Diluted EPS
-CHF 1.65 CHF
Op. Cash Flow
-CHF 51.26M CHF
Free Cash Flow
-CHF 51.97M CHF
Operating Income
-CHF 58.12M CHF
Cash & Equivalents
CHF 82.65M CHF
Debt / Equity
0.00×
Shares Outstanding
40.37M sh
Source: 20-F · filed 2026-03-12 · accession 0001745114-26-000009

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 1 shares in MOLN as of the October 30, 2026 settlement, a 99.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 17, 2026, 0.3% of MOLN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1 shares as of October 30, 2026
Change vs prior period▼ 99.8%
Days to cover1.00 at avg daily volume of 2,297
Daily short volume (FINRA facilities)0.3% of 1,984 shares on November 17, 2026
4-day average short volume29.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

MOLN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with M →
$2.52 -5.25% today
52-week range · as of 2026-10-29 $2.52 – $5.36
Market cap
$98.03M
Volume
930 (0.4× avg)
3-mo avg 2.2K
Live data · 2026-11-22 06:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MOLN - Latest Insights

MOLN
Oct 29, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.71
Real-time Price: $2.53 info
Change: -$1.18 (-32%) info
Market Cap: $98.03M info
MOLN
Aug 25, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.40
Real-time Price: $2.53 info
Change: -$1.88 (-43%) info
Market Cap: $98.03M info
MOLN
Jul 16, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.91
Real-time Price: $2.53 info
Change: -$1.39 (-35%) info
Market Cap: $98.03M info
MOLN
Jul 06, 2026, 6:00 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.99
Real-time Price: $2.53 info
Change: -$1.47 (-37%) info
Market Cap: $98.03M info
MOLN
Jul 02, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.93
Real-time Price: $2.53 info
Change: -$1.41 (-36%) info
Market Cap: $98.03M info
MOLN
May 12, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.53 info
Change: -$1.52 (-38%) info
Market Cap: $98.03M info
MOLN
May 01, 2026, 9:21 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.23
Real-time Price: $2.53 info
Change: -$1.71 (-40%) info
Market Cap: $98.03M info
MOLN
Apr 14, 2026, 4:44 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.14
Real-time Price: $2.53 info
Change: -$1.61 (-39%) info
Market Cap: $98.03M info
MOLN
Mar 30, 2026, 7:06 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.05
Real-time Price: $2.53 info
Change: -$1.53 (-38%) info
Market Cap: $98.03M info
MOLN
Mar 12, 2026, 4:54 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $2.53 info
Change: -$2.19 (-46%) info
Market Cap: $98.03M info
MOLN
Mar 12, 2026, 4:34 PM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $2.53 info
Change: -$2.19 (-46%) info
Market Cap: $98.03M info
MOLN
Mar 12, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.71
Real-time Price: $2.53 info
Change: -$2.19 (-46%) info
Market Cap: $98.03M info
MOLN
Feb 02, 2026, 6:54 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.67
Real-time Price: $2.53 info
Change: -$2.15 (-46%) info
Market Cap: $98.03M info
MOLN
Jan 12, 2026, 5:00 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $2.53 info
Change: -$1.64 (-39%) info
Market Cap: $98.03M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets